Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68248 | 1.00 | CACNA2D1 (0.32) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL68246 | 1.00 | CACNA2D1 (0.32) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL16027887 | 0.98 | KDM4E (0.34) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL16027889 | 0.98 | KDM4E (0.34) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL78956 | 0.83 | GABRR1 (0.43) | GABRR1GABBR2GABBR1 | |
| SCHEMBL80779 | 0.83 | GABRR1 (0.43) | GABRR1GABBR2GABBR1 | |
| SCHEMBL1028103 | 0.83 | GABRR1 (0.43) | GABRR1GABBR2GABBR1 | |
| SCHEMBL1806245 | 0.80 | — | — | |
| SCHEMBL80655 | 0.80 | — | — | |
| SCHEMBL28608405 | 0.80 | CA2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-10577380-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2020-03-03 | — | — | US | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-5364850-A | Analgesics | G. D. SEARLE & CO. (US) | 1994-11-15 | — | — | US | disclosed |
| US-5272175-A | Substituted tyrosyl diamide compounds | G. D. SEARLE & CO. (US) | 1993-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577380-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | CACNA2D1 4163/4885CACNB3 4325/4885CACNA1C 4508/4885 |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | CACNA2D1 908/4885CACNB3 3723/4885CACNA1C 1661/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | CACNA2D1 908/4885CACNB3 3723/4885CACNA1C 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.